Lixte Amends Share Exchange, Clarifies Liora Ownership Structure

Lixte Biotechnology Holdings ( (LIXT) ) just unveiled an update.

On March 6, 2026, Lixte Biotechnology Holdings, Liora Technologies Europe and Orbit Capital executed an Amended and Restated Share Exchange Agreement, effective as of November 21, 2025, to revise and consolidate prior agreements governing their ownership arrangements. The move follows Lixte’s 2025 acquisition of 100% of Liora, the issuance and subsequent exchange of 2,700 shares of Series C Preferred Stock for 700,000 common shares, Orbit’s reacquisition of a 20% stake in Liora, and the termination of a related royalty agreement on December 16, 2025.

The amended agreement is intended to treat all these transactions, including the December 30, 2025 share exchange, as if they occurred on November 21, 2025, creating a single integrated agreement that clarifies the parties’ rights and the final ownership structure. By formalizing this structure, Lixte aims to provide greater transparency and certainty over its relationship with Orbit and Liora, which may reduce future contractual ambiguity and better align stakeholder expectations around control and economic interests in the subsidiary.

More about Lixte Biotechnology Holdings

Lixte Biotechnology Holdings, Inc. is a biopharmaceutical company focused on developing innovative therapies through its subsidiaries, including Liora Technologies Europe Ltd. The company structures its operations and intellectual property through equity holdings and collaboration agreements designed to support its drug development and commercialization efforts.

Average Trading Volume: 76,868

Technical Sentiment Signal: Strong Sell

Current Market Cap: $20.11M

Learn more about LIXT stock on TipRanks’ Stock Analysis page.